The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

1 (tie), Lauren Coughlin and Rio Takeda, 3. 3, 9 tied with 2. 1 (tie), Jaravee Boonchant, In Gee Chun, Jessica Porvasnik, Julia Lopez Ramirez, Miranda Wang and Fiona Xu, 1.00%. 7, Andrea Lee, .88%. 8, ...

Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Protein S is a key vitamin K-dependent plasma protein involved in the regulation of coagulation. Deficiency of protein S, ...

These socks, by Maria La Rosa, look like foil balloons, make a crackling sound when slipped on and, for some people, have ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...